bValue Fund

bValue Fund operates from Warsaw with a portfolio that spans seed through growth investments across Central and Eastern Europe, with a particular emphasis on capital efficiency and operational involvement. The firm distinguishes itself by maintaining an active operational bench of executives who advise portfolio companies on go-to-market, hiring, and digital transformation, which fits with a thesis oriented around technology businesses driving digitization in traditionally underserved sectors. Healthcare exposure runs primarily through digital health and health IT software.

The thesis assumes that CEE businesses can build durable companies on smaller amounts of capital than their Western European or US peers if they are paired with experienced operators who can compress learning curves. Healthcare investments fit into this frame when there is a clear digitization opportunity, an identifiable buyer, and a path to commercial revenue without requiring extended R&D burn. The portfolio leans toward B2B software and tech-enabled services rather than pure deep tech or biotech, reflecting the capital-efficiency mandate.

bValue invests across seed, Series A, Series B, and growth rounds, with checks generally in the $1M to $5M range and the flexibility to follow on across stages. Geographically, the focus is Poland and the broader CEE region, with selective participation in companies operating internationally from a regional base. The stage flexibility means bValue can lead a seed round and continue participating into later financings, which is useful for founders who want continuity rather than rebuilding a board with each round. The firm has historically been more willing than most CEE peers to write follow-on checks at the growth stage.

The team mixes investment professionals with experienced operators, and that structure is intentional. Portfolio companies typically engage with both an investment partner and one or more operating advisors, with the latter focused on specific functional areas like enterprise sales, engineering leadership, or digital transformation. Founders should expect a more involved post-investment relationship than at a typical financial-only fund.

Post-investment, bValue’s most distinctive value is the operational bench, which can be activated for senior hiring, sales process design, and commercial scaling across CEE markets. The firm also helps with follow-on rounds and has working relationships with later-stage European and global funds that can lead growth financings. For healthcare founders, the firm is most useful when the company is selling B2B software into providers, payers, or pharma, where commercial discipline and enterprise sales execution are the primary determinants of outcome. bValue is less suited to founders building deep clinical AI that requires regulatory specialism or to biotech companies with long pre-revenue arcs, since the operational model is calibrated to commercial businesses. Founders considering bValue should welcome an active investor relationship and should be prepared to use the operating bench rather than treating it as ceremonial. The firm is direct in feedback and tends to compress diligence timelines when conviction develops quickly.